Traders should expect upward price pressure as the market digests the positive clinical validation. Monitor for regulatory submission milestones and potential partnership or M&A interest given the high unmet need.
RVMD drugs
RVMD drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 7 $142.51entry
- T+1 · 6mo ago 0.00%α −0.83% · $142.51
- T+5 · 6mo ago +5.21%α +3.71% · $149.94
- T+20 · 6mo ago +9.46%α +6.32% · $155.99
- T+60 · 4mo ago +28.03%α +24.19% · $182.45
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Revolution Medicines announced that Phase 1/2 data for daraxonrasib in RAS-mutant pancreatic cancer were published in NEJM, complementing recently reported positive Phase 3 topline results showing an unprecedented overall survival benefit. The drug holds FDA Breakthrough Therapy and Orphan Drug Designations, reinforcing its potential as a new standard of care for a deadly cancer with limited treatment options.
Key Facts
- NEJM published Phase 1/2 data for daraxonrasib in metastatic RAS-mutant PDAC.
- Company previously announced positive Phase 3 RASolute 302 topline results with unprecedented overall survival benefit vs. standard chemotherapy.
- Daraxonrasib has FDA Breakthrough Therapy and Orphan Drug Designations for PDAC with G12 mutations.
- Daraxonrasib is a RAS(ON) multi-selective inhibitor targeting diverse RAS mutations.
- Three additional global Phase 3 registrational trials are ongoing, including earlier-line PDAC and NSCLC.
Financial Impact
Positive clinical data significantly increases probability of regulatory approval and peak sales potential, estimated by analysts in the multi-billion dollar range for PDAC indication alone.
Risk Factors
- Regulatory approval not guaranteed; pivotal trial results may not replicate in larger populations.
- Competition from other RAS inhibitors (e.g., from Mirati, Amgen) could limit market share.
- Risk of toxicity or safety issues in ongoing broader clinical development.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3289496 |
Track record
44 reports on RVMD
6 of 9 bullish or bearish reports moved the stock their way by T+60. Best: +31.56% at T+60 after the Apr 21, 2026 report. 16 of 17 went positive at some point.
Filters
- Nov 16, 2026today 144 Neutral 3/10 Entry $167.00 Now $166.87 −0.08% settles Feb 16
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $168.20 Now $166.87 −0.79% settles Feb 12
- Nov 13, 20263d ago Insider Cluster Neutral 2/10 Entry $176.02 Now $166.87 −5.20% settles Feb 12
- Nov 12, 20264d ago 144 Neutral 3/10 Entry $176.35 Now $166.87 −5.38% settles Feb 10
- Nov 5, 202611d ago SC 13G/A Neutral 3/10 Entry $177.65 Now $166.87 −6.07% settles Feb 3
- Nov 4, 202612d ago 8-K Bullish 7/10 No price data
- Nov 4, 202612d ago Press Release Neutral 5/10 Entry $177.65 Now $166.87 −6.07% settles Feb 3
- Oct 30, 202617d ago SC 13G Neutral 3/10 Entry $191.31 Now $166.87 −12.78% settles Jan 28
- Oct 23, 202624d ago Institutional Cluster Bullish 4/10 Entry $186.99 Now $166.87 −10.76% settles Jan 21
- Oct 21, 202626d ago Press Release Neutral 1/10 Entry $187.69 Now $166.87 −11.09% settles Jan 20
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers